Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Rothenberg

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 9, 1998
[New cancer therapies: balancing risk and benefit]M L Rothenberg
Oncology (Williston Park, N.Y.)|September 1, 1996
New developments in chemotherapy for patients with advanced pancreatic cancerM L Rothenberg
Cancer Treatment and Research|January 1, 1994
DNA ploidy and S-phase fraction as prognostic factors in cervical cancerM L Rothenberg
The Oncologist|February 13, 2001
Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyondM L Rothenberg
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 1997
Topoisomerase I inhibitors: review and updateM L Rothenberg
Seminars in Oncology|October 24, 1998
Efficacy and toxicity of irinotecan in patients with colorectal cancerM L Rothenberg
Seminars in Oncology|February 1, 1996
CPT-11: an original spectrum of clinical activityM L Rothenberg
Annals of the New York Academy of Sciences|December 13, 1996
The current status of irinotecan (CPT-11) in the United StatesM L Rothenberg
Oncology (Williston Park, N.Y.)|February 24, 2001
Efficacy of oxaliplatin in the treatment of colorectal cancerM L Rothenberg
The Medical Journal of Australia|April 4, 1988
Changing concepts in the management of epithelial ovarian and cervical cancersM L Rothenberg, R C Young
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 9, 1998
[New cancer therapies: balancing risk and benefit]M L Rothenberg
Oncology (Williston Park, N.Y.)|September 1, 1996
New developments in chemotherapy for patients with advanced pancreatic cancerM L Rothenberg
Cancer Treatment and Research|January 1, 1994
DNA ploidy and S-phase fraction as prognostic factors in cervical cancerM L Rothenberg
The Oncologist|February 13, 2001
Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyondM L Rothenberg
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 1997
Topoisomerase I inhibitors: review and updateM L Rothenberg
Seminars in Oncology|October 24, 1998
Efficacy and toxicity of irinotecan in patients with colorectal cancerM L Rothenberg
Seminars in Oncology|February 1, 1996
CPT-11: an original spectrum of clinical activityM L Rothenberg
Annals of the New York Academy of Sciences|December 13, 1996
The current status of irinotecan (CPT-11) in the United StatesM L Rothenberg
Oncology (Williston Park, N.Y.)|February 24, 2001
Efficacy of oxaliplatin in the treatment of colorectal cancerM L Rothenberg
The Medical Journal of Australia|April 4, 1988
Changing concepts in the management of epithelial ovarian and cervical cancersM L Rothenberg, R C Young
Pageof 7